ClinicalTrials.gg
Sign In

DrugBiological

Anti-DKK1 Monoclonal Antibody JS015 clinical trials

Also written JS015.

studies test it
3
open now
2
in phase 3
0
first study started
2023

Keep track of what changes. Save the Anti-DKK1 Monoclonal Antibody JS015 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

JS015
3

Studies by the year they started

3 studies that test it; most in 2023 (1)

Studies that test Anti-DKK1 Monoclonal Antibody JS015, by start year
YearStudies
20231
20241
20251

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
2

What it is tested for

Each study’s main condition, where its own words name it.

Pancreatic Neoplasms
1

Who runs them

Industry 0 · Other 3

Shanghai Junshi Bioscience Co., Ltd. (2) · Fudan University (1)

Often tested with

Tested in the same studies.

Tifcemalimab (1) · JS007 (1) · Irinotecan sucrosofate (1) · Fluorouracil (1) · Leucovorin (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Gemcitabine (1)

Studies

Open first, then newest update. How each study uses Anti-DKK1 Monoclonal Antibody JS015 is read from its arms, and is right about nine times in ten.

Testing it · 3

Given in every arm · 1 — Anti-DKK1 Monoclonal Antibody JS015 is usual care beside what is tested